L&S Knock-Out MRK 12.06.2024/ DE000LX3SGU8 /
5/31/2024 10:00:34 PM | Chg.+0.03 | Bid10:00:34 PM | Ask10:00:34 PM | Underlying | Strike price | Expiration date | Option type |
---|---|---|---|---|---|---|---|
0.27EUR | +12.50% | 0.27 Bid Size: - |
0.28 Ask Size: - |
MERCK KGAA O.N. | 140.00 EUR | 6/12/2024 | Call |
GlobeNewswire
3:29 PM
Medicenna To Present Evidence of Durable Single Agent Activity and Potent Immune Effector Response w...
GlobeNewswire
5/29
Jeito Capital announces the acquisition by Merck & Co (NYSE: MRK) of its portfolio company EyeBio fo...
GlobeNewswire
5/7
CytomX Therapeutics Announces Clinical Collaboration with Merck to Evaluate CX-801 in Combination wi...
GlobeNewswire
5/6
Press Release Biocartis NV: Biocartis and Merck to Collaborate on Improving Patient Access to Person...
GlobeNewswire
3/4
C4 Therapeutics Announces Strategic Discovery Research Collaboration with Merck KGaA, Darmstadt, Ger...
GlobeNewswire
12/21/2023
Arch Biopartners Receives Approval from Ethics Committee in Turkey to Proceed with Phase II Cardiac ...
GlobeNewswire
12/14/2023
ITM Executes License Agreement to Obtain Worldwide Exclusive License for the Clinical Development an...
GlobeNewswire
10/17/2023
ImmunOs Therapeutics Announces Clinical Trial Collaboration with Merck & Co., Inc., Rahway, NJ, USA